Navigation Links
Amgen, Hospira and Sandoz Named Among Top Pharmaceutical Companies with Greatest Biosimilar Drug Potential in United States
Date:5/14/2013

PHILADELPHIA, May 14, 2013 /PRNewswire/ -- The IP & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the release of a life sciences report, "An Outlook on U.S. Biosimilar Competition," providing a comprehensive view of the challenges facing companies entering the United States biosimilar drug market and key players predicted to break into this developing pharmaceutical space.

While the U.S. continues to take steps toward entering the global biosimilar market, it lags behind other nations in this space. The report compares U.S. and EU regulations to underscore the significant differences between these regions and explore ways the U.S. can compete more effectively, in addition to reviewing emerging regulatory developments in India and China. It also identifies potential leaders of the U.S. market, including Amgen, Hospira and Sandoz, among the top three pharmaceutical companies with the most potential to dominate the early stages of biosimilar medications entering the U.S.

Biologic medicines, including biosimilars, are developed using living organisms instead of synthesized chemical compounds and are known to effectively treat a range of conditions including rheumatoid arthritis, metastatic breast cancer, non-Hodgkin lymphoma and anemia. Innovative biologic treatments can cost tens of thousands of dollars per year. Competition from biosimilar therapies will help to lower the cost of these expensive treatments, thus helping to reduce healthcare costs and increase patient access.

"This report is a prime example of the insight that can be gleaned by our internal experts using our high quality, curated life sciences data," said Jon Brett-Harris , managing director, Thomson Reuters Life Sciences.  "Our goal is to provide cutting-edge information and solutions to support our clients making confident decisions related to drug discovery, development and delivery."

"An Outlook on U.S. Biosimilar Competition" was created by Thomson Reuters experts in generic drug and API intelligence. The team utilized Newport Premium, the industry's leading tool for identifying and evaluating generic drug development and licensing opportunities, to compile the report.

View "An Outlook on U.S. Biosimilar Competition."

Learn more about Thomson Reuters Generic and API Intelligence and Newport Premium.

Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minn., Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. Thomson Reuters shares are listed on the Toronto and New York Stock Exchanges. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira dévoile sa stratégie appareil mondiale
2. Hospira enthüllt weltweite Gerätestrategie
3. Hospira revela estrategia global para sus dispositivos
4. Hospira revela estratégia global para dispositivos
5. Hospira Reports First-Quarter 2013 Results
6. Hospira Unveils Global Device Strategy
7. Hospira Names Matthew R. Stober Senior Vice President of Operations
8. Hospira to Host Conference Call for First-Quarter 2013 Results
9. Hospira Announces Executive Changes
10. Hospira Reports Fourth-Quarter and Full-Year 2012 Results
11. Hospira to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... IBM ) Research has today announced new research developments ... retina. The Melbourne based IBM researchers ... in retina images, which could in the future offer doctors ... who may be at risk of eye diseases – such ... world. The research began in 2015 and ...
(Date:2/21/2017)... , Feb. 21, 2017 Diabetic Shoes Market: Overview ... ... be described as a disease, which is marked by high ... and insulin action. The disease has become a global epidemic ... Diabetes affects several organs of the body including eyes, kidneys, ...
(Date:2/21/2017)... -- /PR Newswire/ -- UBM Medica,s Eye Care Group ( ... Modern Retina ( www.modernretina.com ), a new ... Built upon the success of Ophthalmology Times , ... in the areas of retinal surgery, clinical information, research, ... informational needs and filling existing educational gaps, Modern ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... ... Along with Valentine’s Day, February marks American Heart Month, a great time to ... lifetime of heart health. In addition, it is a time to prepare your ... Society of New Jersey (ATSNJ) is urging sports programs to prepare comprehensive guidelines for ...
(Date:2/20/2017)... Wis. (PRWEB) , ... February 21, 2017 , ... ... guidebook offering readers a way to “ Getting Over the Bump in the Road ... tips and lessons learned on how to cope with the ups and downs experienced ...
(Date:2/20/2017)... ... February 20, 2017 , ... Scrubbing in for his ... Houston, Dr. Christopher Pezzi remembers the excitement of the surgeon training him. , “He ... us to do this? Don’t tell anyone, but I would do it for free,’” ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... a cloud-based self-service technology that runs on the Posiflex XT-series of touch screen ... during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is helping ...
(Date:2/20/2017)... ... February 20, 2017 , ... ... you to stop by for a visit this week at HIMSS 2017 Conference ... executives from around the globe. Sensogram will be featured in the conference’s Connected ...
Breaking Medicine News(10 mins):